Life Sciences

  • November 30, 2015

    Teva Launches $6.75B Offering To Back Allergan, Rimsa Deals

    Deal-hungry generic drugmaker Teva Pharmaceutical rolled out a $6.75 billion public offering on Monday as the Israel-based pharmaceutical giant looks to back its acquisitions of Allergan’s generics unit and Mexico-based drug manufacturer Rimsa, according to a statement.

  • November 30, 2015

    Allergan, NY End Antitrust Fight Over Dementia Drug

    Allergan and New York state have settled an antitrust suit that accused the drugmaker of steering patients away from one of its dementia drugs and toward another to avoid competition with generic versions that were coming to market.

  • November 30, 2015

    Montel-Endorsed Apparel Co. Scammed Consumers, FTC Says

    The Federal Trade Commission has accused an apparel company endorsed by talk show host Montel Williams in New York federal court of deceiving consumers into thinking the company's copper-infused compression clothing can alleviate pain.

  • November 30, 2015

    Sheppard Mullin Snags Snell & Wilmer Deal-Maker In LA

    Sheppard Mullin Richter & Hampton LLP said it has shored up its corporate practice group in Los Angeles by tapping a former Snell & Wilmer LLP partner with experience advising on mergers and acquisitions in industries including technology, health care, oil and gas, real estate, biotechnology, entertainment and retail.

  • November 30, 2015

    Actavis Says Travelers Owes Defense In Opioid Abuse Suits

    Actavis PLC asked a California judge Wednesday to rule that Travelers Property Casualty Co. of America must defend it against allegations from the city of Chicago and two California counties that misleading marketing for painkillers has fueled a wave of crime, addiction and expensive health costs.

  • November 30, 2015

    Kirkland Steers Teva In Japanese Generics Venture

    Drugmaker Teva Pharmaceutical, led by Kirkland & Ellis LLP, unveiled a partnership on Monday with Japanese drug developer Takeda Pharmaceutical, setting up the Israel-based pharmaceutical giant for deeper access to the country’s fast-growing generics market, according to a statement.

  • November 30, 2015

    Justices Reject Biolitec's $70M Contempt Appeal

    The Supreme Court on Monday turned away Biolitec AG’s challenge to a $70 million contempt penalty and an arrest warrant for its CEO for going through with a merger expressly forbidden by a lower court’s order.

  • November 30, 2015

    IRS Calls Mylan Patent Deal A 'License' In $100M Tax Fight

    The IRS slammed Mylan Pharmaceuticals’ contention that its $400 million patent deal with Forest Laboratories was a sale rather than a license for tax purposes, telling the U.S. Tax Court that Mylan retained a host of rights and therefore has no basis to challenge a $100 million tax bill.

  • November 30, 2015

    High Court Won't Hear $176M Covidien Prior Art Appeal

    The U.S. Supreme Court on Monday rejected medical supplier Covidien PLC’s efforts to recoup more than $176 million it had been awarded in a patent dispute with a unit of Johnson & Johnson, despite protests that a “secret" prototype shouldn't be considered as prior art.

  • November 30, 2015

    Life Sciences MVP: Sterne Kessler's Eldora Ellison

    Eldora Ellison's time in the laboratory has helped her score victories for biotechs and their cutting-edge treatments, making the Sterne Kessler Goldstein & Fox PLLC director a go-to patent litigator and earning her a spot on Law360's list of 2015 Life Sciences MVPs.

  • November 25, 2015

    MedTel Found In Contempt Again In Heart Monitor IP Fight

    A Pennsylvania federal judge on Monday issued a second order finding heart monitoring company MedTel24 Inc. in contempt of a consent judgment in a patent infringement case brought by CardioNet LLC, but he stopped short of issuing sanctions against it.

  • November 25, 2015

    Pozen Fires Back At Bass Group's Vimovo IPR Petition

    Pozen Inc. has urged the Patent Trial and Appeal Board to reject the latest attempt by an organization tied to hedge fund manager Kyle Bass to obtain an America Invents Act review of a patent covering the arthritis medication Vimovo, saying Bass' group didn’t show that it will succeed in invalidating the patent.

  • November 25, 2015

    P&G Says Fixodent Users' Appeal Is Backed By Bad Evidence

    Proctor & Gamble recently urged the Eleventh Circuit not to revive multidistrict litigation claiming that zinc in Fixodent denture glue can cause neurological damage, saying a lower court didn’t err in concluding scientific evidence submitted by the denture users was too unreliable.

  • November 25, 2015

    Teikoku Loses Bid To Boot 12 Firms From Lidoderm MDL

    A California federal judge on Wednesday refused to disqualify 12 law firms representing retailers in pay-for-delay multidistrict litigation over the Lidoderm pain relief patch, saying plaintiffs’ attorneys’ use of a privileged document mistakenly handed over by Japanese drugmaker Teikoku did not warrant disqualification.

  • November 25, 2015

    Bio-Rad Will Ask 9th Circ. To Nix Whistleblower GC’s Claims

    Bio-Rad Laboratories Inc. is planning to ask the Ninth Circuit to immediately review a California federal court’s recent refusal to toss claims in its former general counsel’s whistleblower suit alleging he was fired after reporting that company leadership potentially engaged in overseas bribery.

  • November 25, 2015

    Medicines Co. Asks Fed. Circ. To Reopen IP Fight With Mylan

    The Medicines Co. on Tuesday asked the Federal Circuit to reopen a case in which it reversed an infringement ruling against Mylan Inc. for a patent for the anticoagulant Angiomax, as the court has agreed to reconsider the patent’s validity in another suit.

  • November 25, 2015

    Wright Hit With $11M Jury Verdict In Hip Implant Bellwether

    An Atlanta jury hit Wright Medical Technology Inc. with an $11 million verdict Tuesday in the first bellwether trial in multidistrict litigation over its allegedly defective metal hip implant, finding that the plaintiff's implant was defective and that the company had misrepresented the safety of the device.

  • November 25, 2015

    Herbalife KOs Pyramid Scheme Suit In Latest Round

    A California federal judge permanently dismissed a securities class action against supplement company Herbalife on Tuesday after finding that multiple opportunities to amend didn't get investors any closer to plausibility on their allegations that the company lied when it denied being a pyramid scheme.

  • November 25, 2015

    WuXi PharmaTech Shareholders OK $3.3B Go-Private Deal

    China-based research and development service provider WuXi PharmaTech on Wednesday said that its shareholders have approved a $3.3 billion deal with a consortium of private equity investors and the company’s founders that will take the company private.

  • November 25, 2015

    Kimberly-Clark Says Rival Recycling Arguments In Diaper Spat

    Kimberly-Clark urged a Wisconsin federal judge not to revive a rival’s claim that patent lawsuits instigated by the Pull-Ups maker demonstrate anti-competitive behavior, telling the judge Tuesday that First Quality is recycling old arguments.

Expert Analysis

  • A New Paradigm For Prescription Drug Labeling?


    The drug industry is anxiously awaiting new regulations from the U.S. Food and Drug Administration that could dramatically alter drug labeling in the U.S. and level the playing field for both generic and brand-name drug companies — but there is a sharp disagreement within the industry on what the FDA should do, say attorneys at Duane Morris LLP.

  • OPINION: In Search Of Our Best Law Firm Selves

    James Maiwurm.jpg

    Several developments over the past few months caught the eye of Jim Maiwurm, chairman emeritus of Squire Patton Boggs. Try as he might, he could not resist the temptation to comment on a few — such as the expansion of the Dentons “polycentric” empire, a confused verein controversy, and provocative suggestions that the law firm partnership model is a dinosaur.

  • A Closer Look At Fed. Circ.’s Ruling In ClearCorrect

    Lyle B. Vander Schaaf

    The Federal Circuit's majority opinion in ClearCorrect seems to provide a sweeping pronouncement regarding U.S. International Trade Commission jurisdiction, but the ITC likely will read the opinion narrowly to simply stand for the proposition that, where the only imported item is digital data that is transferred electronically from outside the U.S., the agency does not have jurisdiction, say Lyle Vander Schaaf and Yashas Honasoge o... (continued)

  • New Federal Rules Acknowledge It’s Time To Drop The 'E'

    Gregory Leighton

    The amendments to the Federal Rules of Civil Procedure scheduled to take effect Dec. 1 are designed to usher in a new era in the U.S. litigation system, this time acknowledging that what was once known as “e-discovery” is now just discovery. The amendments are sweeping in scope, but none is more important than the revised Rule 37(e), say Gregory Leighton and Eric Choi of Neal Gerber & Eisenberg LLP.

  • Class Counsel Fees Getting 'Intense Judicial Scrutiny'

    Carolyn Cole

    Recognizing that defendants have no duty and little incentive to object to an inflated class counsel fee request, and that class counsel have every incentive to increase their fees, Judge Richard Posner and the Seventh Circuit have filled this void by directing “intense judicial scrutiny” of class counsel fee awards. In doing so, the court identified issues all counsel now should consider when crafting a class action settlement, sa... (continued)

  • 3 Ways Technology Is Changing Law Office Designs


    A growing number of attorneys and firms are eschewing tradition by embracing technology to change not only the way we work, but also the way we organize our offices, says Anthony Johnson, founder and CEO of American Injury Attorney Group.

  • 13 Key Business Objectives For Corporate Legal Departments

    Joe Kanka

    Over the past 35 years, Joe Kanka has experienced the corporate legal department from many angles, including management positions at a major law firm litigation support center, two legal staffing companies, and inside AT&T and Bell Atlantic. Here, he shares his 13 key business objectives that corporate legal departments must strive for in today’s business environment.

  • Federal, Calif. 'Slack-Fill' Laws Ensure Fill Of Litigation


    Laws prohibiting nonfunctional slack-fill in product packaging have existed for many years, mostly unnoticed. In recent years, however, district attorneys’ offices and the plaintiffs bar have increasingly initiated slack-fill litigation seeking recovery from a broad range of manufacturers, say attorneys at Sidley Austin LLP.

  • HIPAA Lessons From The Warner Chilcott Settlement

    Ellen L. Janos

    Now that the government has brought criminal charges under the Health Insurance Portability and Accountability Act against Warner Chilcott employees as well as a physician practice owner for alleged unlawful access to, and disclosure of, patient medical records, providers and vendors should re-examine their existing HIPAA policies, says Ellen Janos of Mintz Levin Cohn Ferris Glovsky and Popeo PC.

  • Fed. Circ. Limits Safe Harbor For Post-Approval Conduct

    Brian D. Coggio

    The Federal Circuit’s recent decision in Momenta v. Teva is significant because it not only narrows the scope of safe harbor protection for post-approval conduct but also seemingly eliminates such protection for research tools patents, say Brian Coggio and Ron Vogel of Fish & Richardson PC.